Handa Pharma Business Summary

Handa Pharmaceuticals (6620.TWO) is a Taiwan-based specialty pharmaceutical company that generates revenue through a "dual-engine" strategy of developing high-barrier generics and 505(b)(2) new drugs. Its primary business model relies on licensing agreements, milestone payments, and profit-sharing from a portfolio of niche formulations targeting the U.S. and Chinese markets. Key revenue drivers include the leukemia drug Phyrago, the multiple sclerosis treatment Tascenso ODT, and the gastrointestinal drug Dexlansoprazole DR, with over 60% of current revenue derived from its 505(b)(2) novel formulation segment. Within the competitive landscape, Handa operates alongside major regional players such as Lotus Pharmaceutical, Bora Pharmaceuticals, and ScinoPharm Taiwan, distinguishing itself by focusing on difficult-to-formulate products that offer specific clinical advantages, such as oncology drugs compatible with proton pump inhibitors (PPIs). The company is led by Founder and Chairman Bill Liu, Ph.D., a former executive at Anchen Pharmaceuticals and Yamanouchi Pharma Technologies with over 20 years of experience in controlled-release drug development. The current leadership team includes General Manager Toshiyo Chen, who brings deep commercialization expertise from TSH Biopharm and Pharmira Laboratory, and Executive Vice President of Quality Affairs Maggie Chang, Ph.D. Other key executives include Li Qiao, Ph.D. (SVP and COO), and Michael He, Ph.D. (VP of Product Development). Handa is backed by notable strategic investors, most significantly ScinoPharm Taiwan (a Uni-President affiliate), which serves as its largest external shareholder and primary API partner, alongside institutional support from Taiwania Capital and Catalent, Inc.